TABLE 3.
Clinical characteristics of the patients with AUD stratified by nonprogressive and progressive liver disease
| Characteristics | Nonprogressive (n = 77) | Progressive (n = 43) | p value |
|---|---|---|---|
| Age (years), n = 120 | 44.5 ± 11.5 | 47.7 ± 13.1 | 0.181 |
| Sex (male), n (%), n = 120 | 52 (67.5) | 31 (72.1) | 0.604 |
| BMI (kg/m2), n = 120 | 24.0 ± 3.8 | 25.0 ± 4.0 | 0.191 |
| AST (IU/L), n = 120 | 48.8 ± 44.1 | 104.1 ± 78.3 | <0.001 |
| ALT (IU/L), n = 120 | 41.4 ± 37.4 | 76.9 ± 43.0 | <0.001 |
| GGT (IU/L), n = 118 | 124.4 ± 138.2 | 376.5 ± 401.7 | <0.001 |
| ALP (IU/L), n = 116 | 73.3 ± 15.8 | 90.5 ± 49.1 | 0.031 |
| Bilirubin (mg/dL), n = 120 | 0.5 ± 0.3 | 0.7 ± 0.5 | 0.101 |
| Albumin (g/dL), n = 116 | 4.7 ± 0.4 | 4.6 ± 0.5 | 0.276 |
| INR, n = 118 | 0.97 ± 0.08 | 1.02 ± 0.14 | 0.045 |
| Creatinine (mg/dL), n = 120 | 0.81 ± 0.15 | 0.80 ± 0.13 | 0.715 |
| Platelet count (109/L), n = 118 | 235.5 ± 72.9 | 203.2 ± 95.9 | 0.096 |
| CAP, n = 101 | 256.0 ± 55.2 | 292.3 ± 65.1 | 0.005 |
| LSM (kPa), n = 101 | 4.77 ± 1.15 | 13.97 ± 15.21 | <0.001 |
| CK18‐M65 (U/L), n = 114 | 205.5 ± 112.4 | 673.5 ± 378.0 | <0.001 |
Values presented are mean ± SD. The number of subjects for which data were available is indicated in the first column. The laboratory values are all from T1 (active use).
Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; CK18‐M65, caspase‐cleaved and intact cytokeratin 18; GGT, gamma‐glutamyltransferase; INR, international normalized ratio; LSM, liver stiffness measurement.